PH31260A - Methods for inhibiting angiogenesis. - Google Patents

Methods for inhibiting angiogenesis.

Info

Publication number
PH31260A
PH31260A PH49183A PH49183A PH31260A PH 31260 A PH31260 A PH 31260A PH 49183 A PH49183 A PH 49183A PH 49183 A PH49183 A PH 49183A PH 31260 A PH31260 A PH 31260A
Authority
PH
Philippines
Prior art keywords
chem
inhibiting angiogenesis
methods
piperidino
solvate
Prior art date
Application number
PH49183A
Other languages
English (en)
Inventor
Singh Jai Pal
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PH31260A publication Critical patent/PH31260A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PH49183A 1993-10-15 1994-10-13 Methods for inhibiting angiogenesis. PH31260A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13770393A 1993-10-15 1993-10-15

Publications (1)

Publication Number Publication Date
PH31260A true PH31260A (en) 1998-06-18

Family

ID=22478690

Family Applications (1)

Application Number Title Priority Date Filing Date
PH49183A PH31260A (en) 1993-10-15 1994-10-13 Methods for inhibiting angiogenesis.

Country Status (23)

Country Link
US (1) US5610166A (ja)
EP (1) EP0652000B1 (ja)
JP (1) JPH07149644A (ja)
KR (1) KR950010889A (ja)
CN (1) CN1058390C (ja)
AT (1) ATE205712T1 (ja)
AU (1) AU677701B2 (ja)
CA (1) CA2118097A1 (ja)
CZ (1) CZ287535B6 (ja)
DE (1) DE69428325T2 (ja)
DK (1) DK0652000T3 (ja)
ES (1) ES2161238T3 (ja)
HU (1) HU220607B1 (ja)
IL (1) IL111289A (ja)
NO (1) NO313403B1 (ja)
NZ (1) NZ264674A (ja)
PH (1) PH31260A (ja)
PT (1) PT652000E (ja)
RU (1) RU94036771A (ja)
SI (1) SI0652000T1 (ja)
TW (1) TW303367B (ja)
UA (1) UA32427C2 (ja)
ZA (1) ZA948027B (ja)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
DE69435137D1 (de) 1993-05-13 2008-10-16 Poniard Pharmaceuticals Inc Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
US6197789B1 (en) 1995-06-07 2001-03-06 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US5492927A (en) * 1993-12-21 1996-02-20 Eli Lilly And Company Non-peptide tachykinin receptor antagonists to treat allergy
US5484808A (en) * 1995-02-09 1996-01-16 Eli Lilly And Company Methods of inhibiting cell-cell adhesion
US5843974A (en) * 1995-06-06 1998-12-01 Eli Lilly And Company Methods of inhibiting melanoma using Benzothiophenes as cytotoxic agents per se
US5532254A (en) * 1995-06-07 1996-07-02 Eli Lilly And Company Modulation of calcium channels using benzothiophenes
US6265407B1 (en) 1997-06-24 2001-07-24 Janssen Pharmaceutica N.V. Angiogenesis inhibiting thiadiazolyl pyridazine derivatives
US6537554B1 (en) 1998-09-10 2003-03-25 Curagen Corporation Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis
ATE301129T1 (de) 1999-05-04 2005-08-15 Strakan Int Ltd Androgen glykoside und die androgenische aktivität davon
KR100675252B1 (ko) 2000-03-08 2007-02-08 한국생명공학연구원 신규 7,8-디히드로-잔테논-8-카르복실산 유도체 및 이를생산하는 신규 미생물
US20030104573A1 (en) * 2000-09-11 2003-06-05 Shimkets Richard A. Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis
US6632835B2 (en) 2001-02-22 2003-10-14 Nanodesign Inc. Dibenzo[c]chromen-6-one derivatives as anti-cancer agents
ITMI20011495A1 (it) * 2001-07-12 2003-01-12 Pharmaproducts Uk Ltd Sali di calcio ad attivita' citotossica
JP3887588B2 (ja) * 2002-08-30 2007-02-28 株式会社リガク X線回折による応力測定法
ITMI20041279A1 (it) * 2004-06-24 2004-09-24 Pharmaproducts Uk Ltd Uso di calcio trifluoroacetato per la preparazione di medicamenti ad effetto anti-angiogenetico

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体

Also Published As

Publication number Publication date
CN1105361A (zh) 1995-07-19
SI0652000T1 (en) 2002-06-30
RU94036771A (ru) 1996-11-10
CA2118097A1 (en) 1995-04-16
CZ287535B6 (en) 2000-12-13
EP0652000A1 (en) 1995-05-10
HU220607B1 (hu) 2002-03-28
US5610166A (en) 1997-03-11
JPH07149644A (ja) 1995-06-13
NO943875L (no) 1995-04-18
NZ264674A (en) 1999-06-29
DE69428325D1 (de) 2001-10-25
ES2161238T3 (es) 2001-12-01
PT652000E (pt) 2002-01-30
DK0652000T3 (da) 2001-11-12
ZA948027B (en) 1996-04-15
AU7579194A (en) 1995-05-04
DE69428325T2 (de) 2002-06-20
HUT71108A (en) 1995-11-28
HU9402955D0 (en) 1995-02-28
NO943875D0 (no) 1994-10-13
IL111289A0 (en) 1994-12-29
ATE205712T1 (de) 2001-10-15
CZ253294A3 (en) 1995-05-17
TW303367B (ja) 1997-04-21
CN1058390C (zh) 2000-11-15
UA32427C2 (uk) 2000-12-15
EP0652000B1 (en) 2001-09-19
NO313403B1 (no) 2002-09-30
KR950010889A (ko) 1995-05-15
AU677701B2 (en) 1997-05-01
IL111289A (en) 1999-09-22

Similar Documents

Publication Publication Date Title
HU9403675D0 (en) Methods of inhibiting thrombin
ZA948029B (en) Methods for inhibiting endometriosis
PH31260A (en) Methods for inhibiting angiogenesis.
HU9403667D0 (en) Methods of inhibiting seborrhea and acne
IL111285A0 (en) Methods of inhibiting uterine fibrosis
GR3036983T3 (en) Method for increasing libido in post-menopausal women.
PH31440A (en) Method of inhibiting hirsutism and alopecia in women.